LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 11

Search options

  1. Article: Real-World Data on Second-Line Therapy with Ramucirumab for Metastatic Gastric Cancer: A Two-Center Study on Romanian Population.

    Galos, Diana / Balacescu, Loredana / Vidra, Radu / Sur, Daniel

    Life (Basel, Switzerland)

    2023  Volume 13, Issue 12

    Abstract: 1) Background: Following the results of RAINBOW and REGARD trials, ramucirumab was approved as the standard second-line treatment for patients with advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer, alone or in combination with ... ...

    Abstract (1) Background: Following the results of RAINBOW and REGARD trials, ramucirumab was approved as the standard second-line treatment for patients with advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer, alone or in combination with paclitaxel. The present study aimed to evaluate the efficacy and safety of ramucirumab in the Romanian population during every-day clinical practice. (2) Methods: A two-center, retrospective, observational study evaluated patients with metastatic gastric and GEJ cancer treated with ramucirumab monotherapy or associated with paclitaxel. The patients were treated between 2018 and 2022 in two Romanian centers as follows: 18 patients underwent treatment with ramucirumab monotherapy, while 51 received the combined treatment regimen. Study endpoints included median progression-free survival (PFS), median overall survival (OS), and the evaluation of treatment-induced adverse events (AEs). (3) Results: In the study cohort (n = 69), the most frequent treatment-induced AE in the ramucirumab plus paclitaxel arm was hematological toxicity; the most common AE for patients treated with ramucirumab monotherapy was fatigue and headache. Overall, the median PFS was 4.7 months (95% CI: 3.4-5.9 months) and median OS was 18.23 months (95% CI: 15.6-20.7 months). PFS was correlated with the number of treatment cycle administrations, Eastern Cooperative Oncology Group performance status at treatment initiation, and metastatic site (visceral vs. peritoneal). OS was correlated with the number of treatment cycles administered and human epidermal growth factor
    Language English
    Publishing date 2023-12-05
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662250-6
    ISSN 2075-1729
    ISSN 2075-1729
    DOI 10.3390/life13122300
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Real-World Data on Second-Line Therapy with Ramucirumab for Metastatic Gastric Cancer

    Diana Galos / Loredana Balacescu / Radu Vidra / Daniel Sur

    Life, Vol 13, Iss 12, p

    A Two-Center Study on Romanian Population

    2023  Volume 2300

    Abstract: 1) Background: Following the results of RAINBOW and REGARD trials, ramucirumab was approved as the standard second-line treatment for patients with advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer, alone or in combination with ... ...

    Abstract (1) Background: Following the results of RAINBOW and REGARD trials, ramucirumab was approved as the standard second-line treatment for patients with advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer, alone or in combination with paclitaxel. The present study aimed to evaluate the efficacy and safety of ramucirumab in the Romanian population during every-day clinical practice. (2) Methods: A two-center, retrospective, observational study evaluated patients with metastatic gastric and GEJ cancer treated with ramucirumab monotherapy or associated with paclitaxel. The patients were treated between 2018 and 2022 in two Romanian centers as follows: 18 patients underwent treatment with ramucirumab monotherapy, while 51 received the combined treatment regimen. Study endpoints included median progression-free survival (PFS), median overall survival (OS), and the evaluation of treatment-induced adverse events (AEs). (3) Results: In the study cohort (n = 69), the most frequent treatment-induced AE in the ramucirumab plus paclitaxel arm was hematological toxicity; the most common AE for patients treated with ramucirumab monotherapy was fatigue and headache. Overall, the median PFS was 4.7 months (95% CI: 3.4–5.9 months) and median OS was 18.23 months (95% CI: 15.6–20.7 months). PFS was correlated with the number of treatment cycle administrations, Eastern Cooperative Oncology Group performance status at treatment initiation, and metastatic site (visceral vs. peritoneal). OS was correlated with the number of treatment cycles administered and human epidermal growth factor receptor -2 status. (4) Conclusions: The results support the previously described toxicity profile for ramucirumab monotherapy or associated with paclitaxel and demonstrated a relatively superior median PFS.
    Keywords gastric cancer ; gastroesophageal junction cancer ; metastatic disease ; ramucirumab ; paclitaxel ; second-line treatment ; Science ; Q
    Subject code 616
    Language English
    Publishing date 2023-12-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Challenges of pancreatic cancer chemotherapy in the COVID-19 era.

    Vidra, Radu / Bodea, Raluca / Mercea, Voicu / Nemes, Adina

    Journal of gastrointestinal and liver diseases : JGLD

    2020  Volume 29, Issue 2, Page(s) 273–275

    MeSH term(s) Aged ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Betacoronavirus ; COVID-19 ; Capecitabine/therapeutic use ; Coronavirus Infections/prevention & control ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/therapeutic use ; Female ; Fluorouracil/therapeutic use ; Humans ; Irinotecan/therapeutic use ; Leucovorin/therapeutic use ; Male ; Middle Aged ; Oxaliplatin/therapeutic use ; Pancreatic Neoplasms/drug therapy ; Pandemics/prevention & control ; Pneumonia, Viral/prevention & control ; Romania ; SARS-CoV-2
    Chemical Substances Antineoplastic Agents ; folfirinox ; Oxaliplatin (04ZR38536J) ; Deoxycytidine (0W860991D6) ; Capecitabine (6804DJ8Z9U) ; Irinotecan (7673326042) ; gemcitabine (B76N6SBZ8R) ; Leucovorin (Q573I9DVLP) ; Fluorouracil (U3P01618RT)
    Keywords covid19
    Language English
    Publishing date 2020-06-04
    Publishing country Romania
    Document type Letter
    ZDB-ID 2427021-0
    ISSN 1842-1121 ; 1841-8724
    ISSN (online) 1842-1121
    ISSN 1841-8724
    DOI 10.15403/jgld-2527
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3825: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis.

    Vidra, Radu / Nemes, Adina / Vidrean, Andreea / Pintea, Sebastian / Tintari, Snejeana / Deac, Andrada / Ciuleanu, Tudor

    Experimental and therapeutic medicine

    2021  Volume 23, Issue 1, Page(s) 91

    Abstract: The addition of platinum compounds to standard neoadjuvant chemotherapy (NACT) for triple-negative breast cancer (TNBC) is highly controversial. Platinum agents, such as cisplatin and carboplatin, are DNA-damaging agents which exhibit activity in breast ... ...

    Abstract The addition of platinum compounds to standard neoadjuvant chemotherapy (NACT) for triple-negative breast cancer (TNBC) is highly controversial. Platinum agents, such as cisplatin and carboplatin, are DNA-damaging agents which exhibit activity in breast cancer, particularly in the TNBC subgroup. In order to assess the efficacy of each most representative platinum agent (cisplatin and carboplatin) in patients with TNBC treated with NACT, the present study performed a systematic review and meta-analysis of all available published studies on TNBC. A search of PubMed was performed to identify studies that investigated platinum-based NACT in patients with TNBC. The primary endpoints were the pooled rate of the pathological complete response (pCR) between cisplatin vs. carboplatin-based NACT. A total of 24 studies were selected (17 studies for carboplatin and 6 studies for cisplatin and 1 study with both carboplatin and cisplatin, with 20 prospective studies) for the analysis of 1,711 patients with TNBC. Overall, the pooled rate of pCR in patients treated with platinum-based NACT was 48%. No significant differences were observed between the rates of pCR obtained under carboplatin vs cisplatin treatment. The carboplatin pCR rate was 0.470 [95% confidence interval (CI), 0.401-0.539], while the cisplatin pCR rate was 0.473 (95% CI, 0.379-0.568). The comparison between these two categories revealed no significant differences (P=0.959). In the whole, the present study demonstrates that neoadjuvant platinum-based chemotherapy improves the pCR rate in patients with TNBC, regardless of the platinum agent used. Carboplatin may thus represent a viable option due to its more favorable toxicity profile.
    Language English
    Publishing date 2021-11-26
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 2683844-8
    ISSN 1792-1015 ; 1792-0981
    ISSN (online) 1792-1015
    ISSN 1792-0981
    DOI 10.3892/etm.2021.11014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients.

    Vidra, Radu / Ciuleanu, Tudor Eliade / Nemeș, Adina / Pascu, Oana / Heroiu, Ana Maria / Antone, Nicoleta / Vidrean, Andreea Iulia / Oprean, Cristina Marinela / Pop, Laura Ancuta / Berindan-Neagoe, Ioana / Eniu, Rares / Eniu, Alexandru

    International journal of environmental research and public health

    2022  Volume 19, Issue 7

    Abstract: Background: About 10,000 women are diagnosed with breast cancer and about 2000 women are diagnosed with ovarian cancer each year in Romania. There is an insufficient number of genetic studies in the Romanian population to identify patients at high risk ... ...

    Abstract Background: About 10,000 women are diagnosed with breast cancer and about 2000 women are diagnosed with ovarian cancer each year in Romania. There is an insufficient number of genetic studies in the Romanian population to identify patients at high risk of inherited breast and ovarian cancer. Methods: We evaluated 250 women of Romanian ethnicity with BC and 240 women of Romanian ethnicity with ovarian cancer for the presence of damaging germline mutations in breast cancer genes 1 and 2 (BRCA1 and BRCA2, respectively) using Next-Generation Sequencing (NGS) technology. Results: Of the 250 breast cancer patients, 47 carried a disease-predisposing BRCA mutation (30 patients (63.83%) with a BRCA1 mutation and 17 patients (36.17%) with a BRCA2 mutation). Of the 240 ovarian cancer patients, 60 carried a BRCA mutation (43 patients (72%) with a BRCA1 mutation and 17 patients (28%) with a BRCA2 mutation). In the BRCA1 gene, we identified 18 variants (4 in both patient groups (ovarian and breast cancer patients), 1 mutation variant in the BC patient group, and 13 mutation variants in the ovarian cancer patient group). In the BRCA2 gene, we identified 17 variants (1 variant in both ovarian and breast cancer patients, 6 distinct variants in BC patients, and 10 distinct variants in ovarian cancer patients). The prevailing mutation variants identified were c.3607C>T (BRCA1) (18 cases) followed by c.5266dupC (BRCA1) (17 cases) and c.9371A>T (BRCA2) (12 cases). The most prevalent mutation, BRCA1 c.3607C>T, which is less common in the Romanian population, was mainly associated with triple-negative BC and ovarian serous adenocarcinoma. Conclusion: The results of our analysis may help to establish specific variants of BRCA mutations in the Romanian population and identify individuals at high risk of hereditary breast and ovarian cancer syndrome by genetic testing.
    MeSH term(s) BRCA1 Protein/genetics ; Breast Neoplasms/epidemiology ; Breast Neoplasms/genetics ; Carcinoma, Ovarian Epithelial ; Ethnicity ; Female ; Genetic Predisposition to Disease ; Humans ; Mutation ; Ovarian Neoplasms/epidemiology ; Ovarian Neoplasms/genetics ; Romania
    Chemical Substances BRCA1 Protein ; BRCA1 protein, human
    Language English
    Publishing date 2022-04-04
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2175195-X
    ISSN 1660-4601 ; 1661-7827
    ISSN (online) 1660-4601
    ISSN 1661-7827
    DOI 10.3390/ijerph19074314
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients

    Radu Vidra / Tudor Eliade Ciuleanu / Adina Nemeș / Oana Pascu / Ana Maria Heroiu / Nicoleta Antone / Andreea Iulia Vidrean / Cristina Marinela Oprean / Laura Ancuta Pop / Ioana Berindan-Neagoe / Rares Eniu / Alexandru Eniu

    International Journal of Environmental Research and Public Health, Vol 19, Iss 4314, p

    2022  Volume 4314

    Abstract: Background: About 10,000 women are diagnosed with breast cancer and about 2000 women are diagnosed with ovarian cancer each year in Romania. There is an insufficient number of genetic studies in the Romanian population to identify patients at high risk ... ...

    Abstract Background: About 10,000 women are diagnosed with breast cancer and about 2000 women are diagnosed with ovarian cancer each year in Romania. There is an insufficient number of genetic studies in the Romanian population to identify patients at high risk of inherited breast and ovarian cancer. Methods: We evaluated 250 women of Romanian ethnicity with BC and 240 women of Romanian ethnicity with ovarian cancer for the presence of damaging germline mutations in breast cancer genes 1 and 2 (BRCA1 and BRCA2, respectively) using Next-Generation Sequencing (NGS) technology. Results: Of the 250 breast cancer patients, 47 carried a disease-predisposing BRCA mutation (30 patients (63.83%) with a BRCA1 mutation and 17 patients (36.17%) with a BRCA2 mutation). Of the 240 ovarian cancer patients, 60 carried a BRCA mutation (43 patients (72%) with a BRCA1 mutation and 17 patients (28%) with a BRCA2 mutation). In the BRCA1 gene, we identified 18 variants (4 in both patient groups (ovarian and breast cancer patients), 1 mutation variant in the BC patient group, and 13 mutation variants in the ovarian cancer patient group). In the BRCA2 gene, we identified 17 variants (1 variant in both ovarian and breast cancer patients, 6 distinct variants in BC patients, and 10 distinct variants in ovarian cancer patients). The prevailing mutation variants identified were c.3607C>T (BRCA1) (18 cases) followed by c.5266dupC (BRCA1) (17 cases) and c.9371A>T (BRCA2) (12 cases). The most prevalent mutation, BRCA1 c.3607C>T, which is less common in the Romanian population, was mainly associated with triple-negative BC and ovarian serous adenocarcinoma. Conclusion: The results of our analysis may help to establish specific variants of BRCA mutations in the Romanian population and identify individuals at high risk of hereditary breast and ovarian cancer syndrome by genetic testing.
    Keywords breast cancer ; ovarian cancer ; BRCA mutations ; BRCA1 mutations ; BRCA2 mutations ; Medicine ; R
    Subject code 616 ; 610
    Language English
    Publishing date 2022-04-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article ; Online: Attitudes towards COVID‑19 vaccination in patients with cancer: A cross‑sectional study of 12 oncology centers.

    Lazar, Raluca / Oprean, Cristina Marinela / Badau, Larisa Maria / Miron, Geanina / Draganescu, Loredana / Torok-Vistai, Tunde / Coroian, Iulia / Sabau, Diana / Iliescu, Alexandru / Tamas, Loredana Aracs / Hosu, Sorin / Curca, Razvan / Gatej, Alexandra / Hora, Amalia / Ungureanu, Andrei / Parvu, Doru / Valean, Dan / Usatiuc, Lia Oxana / Vidra, Radu

    Molecular and clinical oncology

    2022  Volume 17, Issue 6, Page(s) 162

    Abstract: Patients with cancer are a high-priority population for COVID-19 vaccination, as per guideline recommendations. The present cross-sectional study was performed to assess the perception of patients with cancer from Romania regarding COVID-19 vaccines. The ...

    Abstract Patients with cancer are a high-priority population for COVID-19 vaccination, as per guideline recommendations. The present cross-sectional study was performed to assess the perception of patients with cancer from Romania regarding COVID-19 vaccines. The study included 932 patients with solid and hematologic malignancies. This was a multicenter study including 12 oncology centers located in Western and Northwestern Romania. Between December 2021 and January 2022, patients with cancer completed an individual paper questionnaire regarding acceptance of the SARS-CoV-2 vaccination, type of vaccine, side effects and source of information. During the first year of the vaccination campaign in Romania, 58.05% (541/932) of the investigated patients received COVID-19 vaccines. The vaccination rate was highest in the 61-70 year age group (61.22%). The most frequently used vaccine was Pfizer-BioNTech (72%). There was a statistically significant association between the rate of vaccination and the area of residence and level of education (P<0.001), with rural residence and a lower level of education being predictive factors for COVID-19 vaccination hesitancy. Patients living in rural areas used non-medical sources (e.g. mass media, social platforms) as their main source of information (53.40%, 204/382), whereas patients living in urban areas (64.90%, 357/550) used predominantly medical sources (e.g. recommendations from oncologists and general practitioners). The main source of information among non-vaccinated patients was mass media (e.g. television, radio); 72.38% vs. 29.67% among vaccinated patients. For the latter, the primary source of information was the recommendations made by oncologists (59.70%) and general practitioners (56.76%). The most commonly reported side effect was injection site pain (20-33% for the first dose and 5-27% for the second dose). In conclusion, the present study confirmed that patients with cancer may be reluctant to receive a COVID-19 vaccine, mainly due to the fear of its potential side effects. Although there is scientific evidence to support the efficacy and safety of vaccines, the primary source of information for patients may affect vaccine uptake, thus affecting the efforts to stop the pandemic. Furthermore, the present study revealed that non-vaccinated patients preferred mass media as their main source of information, whereas vaccinated patients relied on the recommendations made by oncologists or general practitioners.
    Language English
    Publishing date 2022-11-01
    Publishing country England
    Document type Journal Article
    ZDB-ID 2796865-0
    ISSN 2049-9469 ; 2049-9450
    ISSN (online) 2049-9469
    ISSN 2049-9450
    DOI 10.3892/mco.2022.2595
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer.

    Khan, Shah Zeb / Arecco, Luca / Villarreal-Garza, Cynthia / Sirohi, Bhawna / Ponde, Noam F / Habeeb, Baker / Brandão, Mariana / Azim, Hatem A / Chowdhury, Arman Reza / Bozovic-Spasojevic, Ivana / Kovalenko, Iryna / Odhiambo, Andrew / Seid, Fahmi Usman / Mutombo, Alex Baleka / Petracci, Fernando / Vidra, Radu / Altuna, Sara C / Petrova, Mila / Kourie, Hampig Raphael /
    Ozturk, Mehmet Akif / Razeti, Maria Grazia / Lengyel, Csongor György / Talibova, Narmin / Mariamidze, Elene / Sacardo, Karina Perez / Duma, Narjust / Gyawali, Bishal / Trapani, Dario / Tagliamento, Marco / Lambertini, Matteo

    JCO global oncology

    2022  Volume 8, Page(s) e2100153

    Abstract: Purpose: Fertility and pregnancy-related issues are highly relevant for young (≤ 40 years) patients with breast cancer. Limited evidence exists on knowledge, practice, and attitudes of physicians from low- and middle-income countries (LMICs) regarding ... ...

    Abstract Purpose: Fertility and pregnancy-related issues are highly relevant for young (≤ 40 years) patients with breast cancer. Limited evidence exists on knowledge, practice, and attitudes of physicians from low- and middle-income countries (LMICs) regarding these issues.
    Methods: A 19-item questionnaire adapted from an international survey exploring issues about fertility preservation and pregnancy after breast cancer was sent by e-mail between November 2019 and January 2020 to physicians from LMICs involved in breast cancer care. Descriptive analyses were performed.
    Results: A total of 288 physicians from Asia, Africa, America, and Europe completed the survey. Median age was 38 years. Responders were mainly medical oncologists (44.4%) working in an academic setting (46.9%). Among responders, 40.2% and 53.8% reported having never consulted the available international guidelines on fertility preservation and pregnancy after breast cancer, respectively. 25.0%, 19.1%, and 24.3% of responders answered to be not at all knowledgeable about embryo, oocyte, or ovarian tissue cryopreservation, respectively; 29.2%, 23.6%, and 31.3% declared that embryo, oocyte, and ovarian tissue cryopreservation were not available in their countries, respectively. 57.6% of responders disagreed or were neutral on the statement that controlled ovarian stimulation can be considered safe in patients with breast cancer. 49.7% and 58.6% of responders agreed or were neutral on the statement that pregnancy in breast cancer survivors may increase the risk of recurrence overall or only in those with hormone receptor-positive disease, respectively.
    Conclusion: This survey showed suboptimal knowledge, practice, and attitudes of physicians from LMICs on fertility preservation and pregnancy after treatment completion in young women with breast cancer. Increasing awareness and education on these aspects are needed to improve adherence to available guidelines and to promote patients' oncofertility counseling.
    MeSH term(s) Attitude of Health Personnel ; Breast Neoplasms/therapy ; Developing Countries ; Female ; Health Knowledge, Attitudes, Practice ; Humans ; Physicians/psychology ; Pregnancy
    Language English
    Publishing date 2022-03-11
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2687-8941
    ISSN (online) 2687-8941
    DOI 10.1200/GO.21.00153
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  10. Article ; Online: COVID-19 Vaccinations: Summary Guidance for Cancer Patients in 28 Languages: Breaking Barriers to Cancer Patient Information.

    Mauri, Davide / Kamposioras, Konstantinos / Tsali, Lampriani / Dambrosio, Mario / De Bari, Berardino / Hindi, Nadia / Salembier, Carl / Nixon, Joanna / Dimitrios, Tzachanis / Alongi, Flippo / Hameed, Hassan / Valachis, Antonios / Papadimitriou, Konstantinos / Corradini, Stefanie / Popovic, Lazar / Kopecky, Jindrich / Rodriguez, Andres / Antunac, Katarina / Yi, Junlin /
    Lovey, Jozsef / Strojan, Primoz / Saraireh, Haytham / Røtterud, Ranveig / Chojnacka, Marzanna / Olalla, Santa Cruz / Chilingirova, Natalia / De Mello, Ramon Andrade / Amaral, Giovanna Araujo / Arbabi, Farsid / Vidra, Radu / Rapushi, Erjeta / Takeuchi, Dan / Christopoulos, Chirstos / Ivanova, Irina / Djan, Igor / Petricevic, Branka / Cellini, Francesco / Mihaylova, Iglika / Plavetic, Natalija Dedic / Kuhar, Cvetka Grašič / Takeuchi, Elena / Kountourakis, Pantelis / Ntellas, Panagiotis / Gazouli, Ioanna / Gkoura, Stefania / Yuce, Salih / Er, Özlem / Yasmina, Chait / Kumaran, Gireesh / Spahiu, Orges / Yusuf, Aasim / Gono, Paulina / Apostolidis, Kathi / Tolia, Maria

    Reviews on recent clinical trials

    2021  Volume 17, Issue 1, Page(s) 11–14

    Abstract: Background: Covid-19 vaccination has started in the majority of the countries at the global level. Cancer patients are at high risk for infection, serious illness, and death from COVID-19 and need vaccination guidance and support. Guidance availability ... ...

    Abstract Background: Covid-19 vaccination has started in the majority of the countries at the global level. Cancer patients are at high risk for infection, serious illness, and death from COVID-19 and need vaccination guidance and support. Guidance availability in the English language only is a major limit for recommendations' delivery and their application in the world's population and generates information inequalities across the different populations.
    Methods: Most of the available COVID-19 vaccination guidance for cancer patients was screened and scrutinized by the European Cancer Patients Coalition (ECPC) and an international oncology panel of 52 physicians from 33 countries.
    Results: A summary guidance was developed and provided in 28 languages in order to reach more than 70 percent of the global population.
    Conclusion: Language barrier and e-guidance availability in the native language are the most important barriers when communicating with patients. E-guidance availability in various native languages should be considered a major priority by international medical and health organizations that are communicating with patients at the global level.
    MeSH term(s) COVID-19/epidemiology ; COVID-19/prevention & control ; COVID-19 Vaccines ; Humans ; Language ; Neoplasms ; Vaccination
    Chemical Substances COVID-19 Vaccines
    Language English
    Publishing date 2021-12-28
    Publishing country United Arab Emirates
    Document type Journal Article
    ZDB-ID 2251879-4
    ISSN 1876-1038 ; 1574-8871
    ISSN (online) 1876-1038
    ISSN 1574-8871
    DOI 10.2174/1574887116666211028145848
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6436: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top